BriaCell Therapeutics Corporation (BCTX)

CANCER STOCK NEWS: $BCTX delivers at ASCO 2026

✅ 55% 1-year survival
✅27% 2-year survival
✅Heavily pre-treated metastatic breast cancer

This is the kind of dataset that can re-rate a biotech.
#Biotech #StocksToWatch #Healthcare

NEWS: https://bit.ly/3Se0RRi

$LLY $JNJ $PFE @smallcapvoice @StuartSmithSCV

$BCTX notched its 6th consecutive positive DSMB review

No safety concerns and Phase 3 Bria-IMT study in metastatic #breastcancer continues unchanged a key de-risking milestone for investors.

Fast Track + consistent safety signal = momentum building.

read here: https://bit.ly/3Rs5tmM

#Investing #Oncology #Stocks

$BCTX just dropped ASCO 2026 clinical data —and it’s not noise.

✅ Phase 2 median OS: 16.6 months
✅ Positive quality-of-life data in Phase 3
✅ Biomarkers confirming response signals
This is a late-stage oncology play with momentum.

👉 https://bit.ly/4dGr7Li

#biotech #stocks

took a handful

$BCTX " As reported in BriaCell’s recent AACR preclinical poster presentation, Bria-PROS+ demonstrated activation of both adaptive and innate immunity including activation of naïve (resting) T-cells, dendritic cells and natural killer (NK) cells. BriaCell believes these preclinical findings support further clinical evaluation as a potential immunotherapy for prostate cancer. Bria-PROS+ is based on the same Bria-OTS+ platform as Bria-BRES+, BriaCell’s next generation breast cancer immunotherapy candidate, which recently received FDA clearance of its Investigational New Drug (IND) application.

Bria-PROS+ builds on Bria-Cell’s Bria-OTS clinical program in breast cancer, where the first patient dosed experienced the sustained complete resolution of a lung metastasis. This 78-year-old woman with advanced metastatic breast cancer and multiple prior treatment failures achieved complete (100%) resolution of a lung metastasis following four doses of Bria-OTS single agent therapy. The complete response of the lesion, initially observed at 2 months, was subsequently confirmed at 4 months, 6 months, and at 11 months. The patient received 17 cycles of Bria-OTS, completed 12 months of the study, and remains in survival follow-up. "

$BCTX News : BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
https://www.globenewswire.com/news-release/2026/05/13/3293887/0/en/briacell-adds-penn-medicine-s-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study.html

$BCTX BriaCell adds Penn Medicine’s Abramson Cancer Center as a clinical site in its pivotal Phase 3 breast cancer study, further expanding access to its immunotherapy program.

NEWS: https://bit.ly/3PCPxxi

#biotech #oncology #breastcancer #clinicaltrials

$BCTX Phase 3 update:

• 230+ patients enrolled in Bria-IMT trial

• Strong site & patient demand

• Interim results expected in 2026

Potential path toward approval in metastatic breast cancer if survival data is positive.

NEWS: https://t.co/m0s9bNNz4n

#BiotechStocks #Investing

My best estimate: approximately 260 enrolled today, reflecting the sharp uptick in site and patient interest since the Nature Medicine feature — now at 70+ active sites.
Of those, approximately 100 are in the TPC arm. With a median OS of approximately 8 months in this heavily pretreated population, exponential decay math puts 85-90 of them already as events. The remaining 54 needed for the 144-event threshold are coming from the experimental arms — roughly 50 patients there have 20+ months of follow-up, well past the 15.6-month Phase 2 median.
Running the numbers across scenarios: if Bria-IMT is performing at Phase 2 levels (median OS approximately 15.6 months), we are at or past 144 events already. If it is outperforming — say median OS 25+ months — we are just below the threshold. Either way, after June every single day without an interim announcement is itself a data point. The longer the silence, the better the drug may be working.
On dilution: four raises since early 2025, the last a 30 million dollar offering in January 2026 at 5.59 per unit. Par for the course in clinical-stage biotech — and with zero debt, a current ratio of 3.42, and a float that remains small, the capital structure is cleaner than the headlines suggest. At approximately 30 million market cap, the market is still pricing this as if the trial doesn’t exist.
Holding. Watching the calendar, not the ticker.

$BCTX expands its Phase 3 Bria-ABC trial with NYU Langone’s Perlmutter Cancer Center now onboard, further advancing its Bria-IMT immunotherapy in metastatic breast cancer.


NEWS: https://bit.ly/4naW9PK

#Biotech #Healthcare #Oncology #ClinicalTrials

$BCTX gets FDA clearance to initiate clinical evaluation of Bria-BRES+. A key regulatory milestone that advances the program and strengthens the company’s position in innovative cancer immunotherapy.


News: https://globenewswire.com/news-release/2026/05/06/3288700/0/en/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer.html

🥺BriaCell wins FDA clearance to start Bria-BRES+

$BCTX to showcase six clinical data presentations at ASCO 2026, including final randomized Phase 2 Bria-IMT survival and quality of life data plus biomarker analyses from its ongoing Phase 3 study. A major catalyst to watch as the company advances.
https://globenewswire.com/news-release/2026/04/27/3281510/0/en/briacell-announces-six-clinical-data-presentations-at-asco-2026.html

#Stocks #stockstobuy #stockstowatch #investors #BCTX

$BCTX highlights powerful preclinical data for Bria-OTS+ at AACR Next-gen immunotherapy advancing toward clinical entry this year.

Read more: https://globenewswire.com/news-release/2026/04/21/3277803/0/en/briacell-presents-robust-anti-cancer-activity-of-bria-ots-in-preclinical-cancer-models.html

#BCTX #AACR #cancerstock #briacell #stocks @smallcapvoice

Ah yes, another “positive update” followed by a perfectly traditional 10% drop on what can only be described as a gentleman’s volume.
At this point, one might humbly suggest that silence could be the company’s most bullish strategy — at least until approval arrives and spoils the market’s favourite pastime of selling good news.
Quite remarkable, really. One almost admires the consistency.

$BCTX: presented positive Phase 3 quality of life data and new Phase 2 biomarker findings - In heavily pretreated metastatic breast cancer patients, QOL remained largely preserved - biomarker analysis could help identify patients most likely to benefit. https://bit.ly/3QyldE6

Topline interim data readout expected in 1H2026 … If everything goes well, starting in September, every extra day is one step closer to glory. The harder the challenge, the greater the triumph.
https://www.globenewswire.com/news-release/2025/12/09/3202256/0/en/BriaCell-s-Phase-3-Patient-Enrollment-on-Track-for-1H2026-Topline-Data-Readout.html

BriaCell will present four posters at the American Association for Cancer Research (AACR) Annual Meeting on April 17-22, 2026
https://clinicaltrials.gov/study/NCT06072612

$BCTX to showcase momentum at AACR 2026 BriaCell will present positive Phase 3 data for Bria-IMT™ plus new preclinical results for Bria-OTS+™, highlighting efficacy, safety, and preserved quality of life in late-stage breast cancer.



Read more about the posters here: https://globenewswire.com/news-release/2026/03/18/3258061/0/en/BriaCell-to-Present-Positive-Clinical-Data-for-Bria-IMT-and-Preclinical-Data-for-Next-Generation-Bria-OTS-Personalized-Immunotherapy-at-the-2026-AACR-Conference.html

Bounce Alert: Is $BCTX ready for a rebound in the markets with its recent Phase 3 study of Bria-IMT in combination with an immune checkpoint inhibitor and its Bria-OTS+ personalized off-the-shelf immunotherapy program. https://globenewswire.com/news-release/2026/03/10/3252671/0/en/BriaCell-to-Present-Four-Poster-Presentations-at-the-2026-AACR-Annual-Meeting.html

$BCTX strengthens oncology pipeline as sub BriaPro Therapeutics secures exclusive worldwide rights to sCD80, a novel immunotherapy licensed from shown to stop tumor growth in preclinical studies. BriaCell commits up to $3M to accelerate development. https://globenewswire.com/news-release/2026/02/18/3240709/0/en/BriaCell-and-BriaPro-Enter-Into-Asset-Purchase-Agreement-for-Exclusive-Soluble-CD80-License.html

BriaCell Therapeutics (Nasdaq: $BCTX ) receives its 5th consecutive positive DSMB recommendation, with no safety concerns and continued progression of its pivotal Phase 3 metastatic breast cancer study: https://globenewswire.com/news-release/2026/02/17/3239128/0/en/BriaCell-Receives-Positive-Recommendation-from-Data-Safety-Monitoring-Board-DSMB-for-Phase-3-Study-in-Metastatic-Breast-Cancer.html

$BCTX Stock Alert: This stock is on the precipice of BIG things with Patients’ Images Show Regression and Resolution of Metastasized Tumors - Images confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, and spine lesions

News: https://globenewswire.com/news-release/2026/01/28/3227515/0/en/BriaCell-Patients-Images-Show-Regression-and-Resolution-of-Metastasized-Tumors-and-Immune-Activation.html

$BCTX Furthers Advancements with encouraging Phase 2 progress in metastatic breast cancer. 9 patients remain alive 18 to 47 months post enrollment, well beyond typical benchmarks.

READ THE NEWS: https://www.globenewswire.com/news-release/2026/01/27/3226377/0/en/BriaCell-Highlights-Extended-18-47-Months-Survival-in-Phase-2-Metastatic-Breast-Cancer-Patients.html

https://investorshub.advfn.com/stock-market/NASDAQ/briacell-therapeutics-BCTX/stock-news/97694162/briacell-highlights-extended-18-47-months-surviva
BriaCell is not about chasing a couple of extra months of PFS. It is about long-tail survival — where some patients live years instead of months. That profile naturally prolongs trials, blurs short-term forecasts, but is exactly how real oncology blockbusters are born. Ultimately, the most meaningful validation would be the entry of a major pharmaceutical player as a strategic partner or shareholder.
The data look good… but somehow, never a moment of joy.

$BCTX reports strong clinical momentum. Bria-OTS delivered a sustained 100% resolution of lung metastasis at 11 months in a late-stage breast cancer patient, with no treatment-limiting toxicities reported.


News: https://www.globenewswire.com/news-release/2026/01/13/3217681/0/en/BriaCell-Reports-Sustained-Complete-Resolution-of-Lung-Metastasis-in-Bria-OTS-Patient.html

BCTX BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient https://investorshub.advfn.com/stock-market/NASDAQ/briacell-therapeutics-BCTX/stock-news/97605429/briacell-reports-sustained-complete-resolution-of

Nature Medicine highlights BriaCell’s Phase 3 metastatic breast cancer trial as one of the “11 clinical trials that will shape medicine in 2026.”

Top line data expected as early as H1 2026.

$BCTX featured as a clinical trial to watch.

NEWS: https://globenewswire.com/news-release/2025/12/18/3207604/0/en/Eleven-clinical-trials-that-will-shape-medicine-in-2026-BriaCell-Phase-3-Trial-Featured-in-Nature-Medicine.html

$BCTX BriaCell presents positive clinical data in three posters at the San Antonio Breast Cancer Symposium (SABCS®)
Phase 3 study of Bria-IMT™ plus immune check point inhibitor (CPI) continues to support biomarkers to identify patients who benefit from treatment with BriaCell’s regimen
Maturing Phase 2 study data continues to support meaningful clinical benefit of the Bria-IMT regimen with outstanding long-term survival
No toxicity related discontinuations in Phase 3

BriaCell ( $BCTX ) shows strong Phase 2 survival and promising Phase 3 biomarker data at SABCS 2025: outstanding long term survival and no toxicity related discontinuations.



Read the full press release here: https://globenewswire.com/news-release/2025/12/10/3203069/0/en/BriaCell-Presents-Outstanding-Phase-2-Survival-Promising-Phase-3-Clinical-Data-at-SABCS-2025.html

Great News from $BCTX: Phase 3 combination regimen continues under FDA Fast Track designation - reports strong momentum in its Phase 3 MBC study with 160+ patients enrolled. ““The pace of patient enrollment in our pivotal Phase 3 study has exceeded expectations” CEO

News: https://globenewswire.com/news-release/2025/12/09/3202256/0/en/BriaCell-s-Phase-3-Patient-Enrollment-on-Track-for-1H2026-Topline-Data-Readout.html

BriaCell is entering a rare position for a small-cap biotech: a true binary event with substantial upside and meaningful de-risking already in place.
🔹 Why the setup is compelling:
• Exceptional upside potential (uncommon in small-caps)
• Real de-risking driven by multiple predictive biomarkers
• Outstanding safety profile, especially for a cellular immunotherapy
• Early Phase 3 signals already encouraging
BriaCell stands out as the only allogeneic immuno-cellular therapy in breast cancer with:
• Overall Survival (OS) signals in Phase 2
• Initial PFS improvement in Phase 3
• Well-defined predictive biomarkers (NLR, DTH, Th1 signatures)
• Clear clinical benefit in HR+/HER2-low populations

Partnerships or Big Pharma Interest
Big pharma companies do not invest unless there is:
• a validated biomarker,
• a strong safety profile,
• and a credible pathway to approval.

BriaCell now has:
• biomarkers (NLR, DTH, Th1 signatures),
• excellent safety,
• a true Phase 3 program underway.

This is the first time in the company’s history where it can realistically attract major pharmaceutical partners.
• Excellent safety, even in heavily pre-treated patients

$BCTX presents strong preclinical data at SITC 2025: Bria-OTS+ rapidly activates both innate and adaptive immunity, producing potent, durable tumor-killing results. Lead programs Bria-BRES+ and Bria-PROS+ continue advancing. https://globenewswire.com/news-release/2025/11/07/3183561/0/en/BriaCell-Presents-Robust-Anti-Cancer-Activity-of-Bria-OTS-at-SITC-2025.html

BriaCell Therapeutics ( NASDAQ: $BCTX ) will present new data showing robust anti-cancer activity from its next-gen Bria-OTS+™ platform at SITC 2025. Backed by a $2M NCI award, BriaCell advances Bria-BRES+™ and Bria-PROS+™ toward clinical trials. https://globenewswire.com/news-release/2025/11/04/3180205/0/en/BriaCell-to-Present-Robust-Anti-Cancer-Activity-of-Bria-OTS-in-Breast-and-Prostate-Cancer-Models.html

Cancer Stock Alert: The Positive News Keeps Coming for $BCTX Phase 3 study is being conducted under FDA Fast Track Designation - Company addressing significant unmet need in metastatic breast cancer News: https://globenewswire.com/news-release/2025/10/22/3170997/0/en/BriaCell-Receives-Positive-Recommendation-from-Data-Safety-Monitoring-Board-DSMB-for-Phase-3-Study-in-Metastatic-Breast-Cancer.html

Cancer Stock Alert: $BCTX Up Over 15% in Response to NEWS: https://globenewswire.com/news-release/2025/10/21/3170083/0/en/BriaCell-Announces-Collaboration-with-MSK-Accelerator-to-Advance-Bria-OTS-for-Breast-Cancer.html

BriaCell $BCTX to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025 NEWS: https://globenewswire.com/news-release/2025/10/13/3165447/0/en/BriaCell-to-Present-Positive-Clinical-Biomarker-Data-of-Phase-3-Study-at-ESMO-2025.html

$BCTX announces peer-reviewed validation of its Bria-OTS+™ immunotherapy in JCI Insight. Backed by NCI data, the study highlights Bria-OTS+ cancer-killing potential and its role in addressing urgent unmet needs in oncology: https://globenewswire.com/news-release/2025/08/26/3139167/0/en/BriaCell-s-Bria-OTS-Mechanism-of-Action-Validated-in-Highly-Rated-Peer-Reviewed-Cancer-Journal.html

$BCTX awarded $2.05M non-dilutive grant from NCI to advance Bria-PROS+™ in metastatic prostate cancer. Read more: https://finance.yahoo.com/news/briacell-awarded-2-million-nci-113000635.html

$BCTX News Alert! BriaCell progress update: Bria-OTS+, a next-gen off-the-shelf immunotherapy, continues development. Check the PR for full details: https://globenewswire.com/news-release/2025/08/13/3132482/0/en/BriaCell-Selected-for-MSK-s-2025-Therapeutics-Accelerator-Program-for-Bria-OTS-for-Cancer.html

BriaCell Therapeutics (NASDAQ: BCTX), a clinical-stage biotechnology company, has announced a 1-for-10 share consolidation to maintain Nasdaq listing compliance. The consolidation is expected to take effect on August 25, 2025, with post-consolidation trading beginning around August 26, 2025, subject to TSX and Nasdaq approval.

Is R/S 1 for 10 effective 08/25.?

BCTX 0.65 mcap 12m - Phase 3 cancer play nearing readout and potential BLA filing by next year ,trading below its cash of 26 million , a mega opportunity here

H.C. Wainwright maintains $32 target on BriaCell stock
https://www.investing.com/news/analyst-ratings/hc-wainwright-maintains-32-target-on-briacell-stock-93CH-3998234

fact Sheet
https://irp.cdn-website.com/5f887d33/files/uploaded/20250717-BriaCell+Fact+Sheet-Website.pdf

$BCTX $BCTXW BriaCell has been granted New Zealand Patent No. 785587 titled “WHOLE-CELL CANCER VACCINES AND METHODS FOR SELECTION THEREOF”. For additional information,

visit: https://bit.ly/45cSZ5w

When I see sunsets... I don't like it!
17.55 M shares outstanding
https://www.stocktitan.net/sec-filings/BTCT/schedule-13g-btc-digital-ltd-sec-filing-bd23f0a68e5c.html

Chic price… for short!

It's likely someone will see the possibility of keeping it under 1... Who knows if they'll succeed? Meanwhile, yesterday there were few red lines.

The market sets the price... a bargain!
It all sounds like bullshit, and maybe it is, but science convinces me, so I Hold on

0,73!
I added!

Cancer Stock Alert: $BCTX adds the Mayo Clinic to its pivotal Phase 3 trial in metastatic breast cancer, expanding to 59 sites across 15 states. The Bria-IMT combination regimen has received FDA Fast Track designation! This is BIG news https://globenewswire.com/news-release/2025/07/15/3115474/0/en/BriaCell-Adds-Mayo-Clinic-to-Phase-3-Study-in-Metastatic-Breast-Cancer.html

BriaCell Adds Mayo Clinic to Phase 3 Study
wow
I will add